Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm seeing full sugar Xing all over the place. I thought it wasn't a seller?
You can't ask for a better set up.
As we all know, the antibiotic drugs/companies like PRTK etc, have been ignored, or beaten for a while now, but the tide is starting to turn. The threat of antibiotic resistance is growing, and new drugs to help slow it down or potentially stop it, will be at a premium. Look, for example, 12 hours ago, a new class of "dirt" antibiotics, was discovered. Look at the big publicity for it:
http://www.bbc.com/news/health-43032602
The "dirt" antibiotics are a long way from human testing and potential approval. So what new antibiotic, the first one likely to be approved in 10 years, later this year, will be coveted by the press and by investors????
PRTK, is a rare opportunity to buy in to a company that is in an arena that has been overlooked, and quite frankly, sold off to oblivion. Now is the time to load up and hold. That's what I have done fwiw.
A reversal has begun. Friday was the hammer and today is the first green candle. Expect 20 plus in a month or two. Market cap is unreasonably low.
Pepsi or Coke getting into the seltzer business and hasn't entered the carbonated coco fruity flavors yet. Fizz should dive with serious competition. The real question is whether NBEV can keep up the momentum with so many me too products from other companies out there. Commodity city.
The market is taking everything down with it. Patience will pay. Hold on tight.
Added a bunch more. Patience will pay here.
Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycl...
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that on February 2, 2018, it completed the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the Company’s once-daily oral and IV formulations of its broad-spectrum investigational antibiotic, omadacycline. Omadacycline is the first in a new class of tetracycline antibiotics known as aminomethylcyclines. Paratek is seeking FDA approval for omadacycline for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), based on the results of three successful Phase 3 pivotal studies. The FDA has previously granted omadacycline both Qualified Infectious Disease Product and Fast Track designation for these indications, which provide for a Priority Review of the NDAs, once accepted.
“The completion of our NDA submissions marks a significant milestone for Paratek and we are deeply grateful to the patients, investigators, and entire Paratek team for their commitment to advancing omadacycline’s development path to this major milestone,” said Evan Loh, MD, President, COO & CMO of Paratek. “With antibiotic resistance on the rise, we look forward to working with the FDA during the regulatory review process with the goal of bringing a modernized tetracycline antibiotic, omadacycline, to clinicians and patients for the treatment of serious community-acquired bacterial infections.”
The NDAs are supported by the Company’s Phase 3 program for omadacycline, which includes three pivotal registration trials: two studies in ABSSSI and one study in CABP. Omadacycline met all FDA and European Medicines Agency (EMA) primary endpoints in each study and demonstrated a generally safe and well-tolerated profile.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The Company’s lead product candidate, omadacycline, is a new, once-daily oral and intravenous broad-spectrum antibiotic being developed for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the target indications of ABSSSI, CABP, uUTI and cUTI. Paratek has completed Phase 3 development activities for omadacycline in CABP and ABSSSI and has completed its New Drug Applications to the U.S. FDA and is preparing a marketing authorization in the European Union. Paratek has licensed rights for omadacycline to Zai Lab for the greater China region and retains all remaining global rights.
Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.
Paratek's second Phase 3 product candidate, Seysara™ (sarecycline), is being developed by Allergan in the U.S. as a new once-daily oral therapy for the treatment of acne. Allergan has completed Phase 3 development activities for Seysara and its new drug application was accepted for review by the U.S. FDA in December 2017. Paratek retains all ex-U.S. rights to sarecycline.
Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.
CONTACTS:
Media Relations: Investor Relations:
Michael Lampe Hans Vitzthum
(484) 575-5040 LifeSci Advisors, LLC.
michael@scientpr.com (617) 535-7743
Primary Logo
Did anybody see the flag football game that NBEV sponsored? No commercial, just handing out freebies to the gang playing? Oh well, these things take time. Look at FIZZ, they made a fortune on horrible selzer water with zero taste. Amazing how they pulled that scam off. Just make pretty looking cans and sell carbonated tap water with a touch of "natural flavoring".
It just goes to show, BW is immune to the 6th biggest daily decline in history.
If they sell.........................
Kudos to New Jericho Man for correctly guessing the CL sale among other things. Hats off.
The lack of filings is becoming tiresome. The jury is out of Stevo. Check back in a year...perhaps he will file by then?
The Xing Tea Master Craft have Ginseng?
This video tells the PRTK potential. Very compelling:
I wonder if the Lebon's were part of the sell off from last August? Or maybe they are beginning that process now? See you at 2.25 if that's the case.
Sparkling coco water is going to be made by every Tom, Richard, and Harry. NBEV has to get it out there asap. Kalena sparkling coconut water might be a beast: https://www.kalenasparkling.com/ Uh oh.
Wow 36k healthclubs carrying NBEV's products? Yuge!!!!!
It's definitely possible when a total crap product like Lacroix hit a home run. Most likely, a science division drink will be rext next hr for Nbev. The cancer causing cell phone radiation might be a nationwide call for action to use nbev's anti-radiation drink enmasse. A national call to prevent the upcoming cancer epidemic!
Though the sugar is a tad high, in a well balanced diet, you can still drink a full can a day and lose weight or maintain health. It's poisonous only to those that neglect their health.
Added some more at the 15.70 range. May need to do another round if this keeps up.
Ok..My review of Xing Tea in honor of the recently departed Lebons:
1. Nice flavors mixed in with the tea (blueberry, mango, pomegranate).
2. No off flavors or after taste.
3. Just enough underlying tea flavor to base the flavors.
4. A tad too much sugar at 48 grams a 24 oz can.
5. At the 9.99 December special, the use cost per 24 ounce can was under 70 cents.
6. May need to tamp down the cane sugar since it's combined with honey.
7. The Ginseng provides a nice stimulating ride.
8. Overall: 9 out of 10 rating.
When this is at $50, what excuse will you have?
BW only graduated from West Point. Yeah, he must be a light weight like you suggest.
BW has to sweep out the trash. Those boys were old news and didn't know how to go to the next level Do some d/d.
Maybe they were the ones selling since last August?
The price has gone through the roof and now the sales are flowing.
The replenishment rate of Marley tea may be surprising.
SURGE BLOCKCHAIN SIGNS CONTRACT FOR OKLAHOMA UTILITY PAYMENTS
Surge Blockchain finalizes an agreement to partner with the Oklahoma Municipal League (OML) in facilitating payments for utility customers across the state. Oklahoma has more than 1.7 million households within its more than 500 municipalities. Details on the contract will be released soon regarding how the Surge Blockchain software technology will assist residents of Oklahoma in making more convenient and timely payments while fostering local economic growth.
The mission of the OML is to provide services and programs for municipal officials to assist them in better serving their citizens, and to act as the representative of Oklahoma municipalities in interactions requiring a united voice. Since 1913, the League has served as the individual and collective voice of local officials on the state and national level.
https://surgeholdings.com/2018/01/24/surge-blockchain-signs-contract-oklahoma-utility-payments/
People will be wondering six months to a year from now why they didn't load up in the 15/16 range. Now is the time to back up the truck. The video below spells out how big of an opportunity this is for tiny PRTK:
This is a good youtube summary of the resistance issue and how PRTK can make a huge difference with Omadacycline:
Learn how investigational omadacycline is designed to overcome the 2 main mechanisms of tetracycline resistance:
Dude, sometimes it's better not say anything than say something and look like a tool right? lol
The chat rooms, i.e. awesome calls with huge subscribers, pushed this up with the huge volume. Now, the volume is starting to dry and the stock will become a show me stock before the CVS/Military news. We will see.
My sources tell me the re-order rates are excellent.
I like your DD the best of all,
Looks like the US Military believes in BW. What a glorious victory for team NBEV!
Started a new position today at $16.25 and may have to take advantage of cheapies.
The two drugs will probably be approved and improve the prospects of this company regardless of the stupid $50 million offering. The bottom line is that the float is pretty small, and the potential is large to hit $50 or more with the present market cap at $444 million. That's a relatively small market cap making this one of the best antibiotic/acne drug company opportunities in a while?
The US Military saw substantial benefit in buying lots and lots of products. Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
NBEV yuge military sales!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!